Amylyx Pharmaceuticals (AMLX) Stock Price & Analysis
Score
AI Analysis
SnapshotAmylyx Pharmaceuticals doesn’t screen as a clean setup today — Stocklytics 66/100 leaves more to prove. Under the hood: revenue compounding ~479% annually over recent years.
Price History
Price: —
Fair value: —
—
P/E (TTM): —
Net Income (TTM): —
Score: —
—
Score Breakdown
Market percentile scores loading…
Value
Growth
Quality
Financial Summary
Amylyx Pharmaceuticals, Inc. (AMLX) last printed $30.29. Equity value is $3.89B. Trailing earnings multiple —. The revenue row is reported history. Targets and ratings are on the forecast page.
Financials
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|
| $1.43M | $650,000.00 | $0.00 | $22.23M | $380.79M | $87.37M | $0.00 |
About
Amylyx Pharmaceuticals, Inc. operates as a clinical-stage biopharmaceutical firm, primarily focused on creating therapies for amyotrophic lateral sclerosis (ALS) and various other neurodegenerative conditions. A key asset in its developmental pipeline is AMX0035, a proprietary dual UPR-Bax apoptosis inhibitor. This compound, which integrates sodium phenylbutyrate and taurursodiol, is under investigation for treating ALS, and its application is also being explored for other neurodegenerative diseases. The company was established in 2013 and is based in Cambridge, Massachusetts.